Sentante launches commercial rollout of its physical AI platform for vascular surgery and interventional radiology after obtaining EU CE mark
Executive summary: Sentante commenced commercial rollout of its physical AI platform in vascular surgery and interventional radiology, with the first clinical case conducted in Kaunas, Lithuania on August 25, 2026, after obtaining a CE mark in May 2026. This represents one of the first real‑world deployments of endovascular physical AI, potentially improving procedural precision and opening a new revenue stream for the medtech AI sector while setting a precedent for future AI‑enabled surgical tools.
Who is involved: Sentante (technology developer), the Lithuanian clinical team in Kaunas that performed the inaugural case, EU regulators who granted the CE mark, and hospitals adopting the system.
Likely next: Sentante will continue expanding the rollout to additional EU sites, collect real‑world data to refine its AI models, and prepare further regulatory submissions (e.g., FDA) for broader international distribution.
Sentante has begun the commercial deployment of its physical AI system in the vascular surgery and interventional radiology specialties, starting with the first procedure performed in Kaunas, Lithuania on August 25, 2026. The rollout follows the company’s receipt of a CE mark under the EU Medical Device Regulation in May 2026, which authorizes the device for sale in European markets. This move positions Sentante as an early mover in the clinical application of endovascular physical AI, a niche that could influence procedural efficiency and patient outcomes.
Timeline
- — Sentante takes physical AI to market, beginning commercial rollout in vascular surgery and interventional radiology (PR Newswire)
Analysis — what this means
Sectors affected
- vascular surgery devices
- interventional radiology equipment
Regulatory implications
- Sentante's platform obtained CE marking under the EU Medical Device Regulation (MDR) in May 2026, allowing legal commercial distribution in the European Union
Historical parallels
- Intuitive Surgical's da Vinci robotic system received FDA clearance in 2000 for laparoscopic surgery
- IBM Watson for Oncology was introduced in 2013 as an AI‑driven cancer treatment recommendation tool
Sources
- Sentante takes physical AI to market, beginning commercial rollout in vascular surgery and interventional radiology — PR Newswire